New drug combo aims to shrink throat tumors before surgery

NCT ID NCT07248956

Recruiting now Disease control Sponsor: Eye & ENT Hospital of Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the drug finotonlimab to standard chemotherapy before surgery can improve outcomes for people with advanced hypopharyngeal cancer (a type of throat cancer). About 116 adults who have not had prior treatment will be randomly assigned to receive either chemo alone or chemo plus finotonlimab. The goal is to see if the combination helps prevent the cancer from coming back or spreading.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOPHARYNGEAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypopharyngeal carcinoma hypopharynx cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOPHARYNGEAL CARCINOMA

Contacts and locations

Locations

Beijing Tongren Hospital, Capital Medical University
NOT_YET_RECRUITING

Beijing, China
Cancer Hospital Chinese Academy of Medical Sciences
NOT_YET_RECRUITING

Beijing, China
Eye & ENT Hospital, Fudan University
RECRUITING

Shanghai, China
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITING

Harbin, Heilongjiang, China
Shandong Provincial ENT Hospital
NOT_YET_RECRUITING

Jinan, Shandong, China
Tianjin Medical University Cancer Institute & Hospital
NOT_YET_RECRUITING

Tianjin, China
Zhongshan Hospital of Fudan University
NOT_YET_RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.